Gastroesophageal Junction Cancer News

News

Second-Line Anlotinib Plus Toripalimab Demonstrates Safety, Efficacy in Advanced Gastric or Gastroesophageal Junction Carcinoma

12/20/2022

Allison Casey

A single-arm study found that anlotinib combined with toripalimab is an effective and safe second-line treatment for patients with gastric or gastroesophageal junction carcinoma.

A single-arm study found that...

12/20/2022

Oncology

News

FLOT Chemotherapy and CROSS Trimodality Regimen Result in Equivalent Survival for Patients With Gastroesophageal Junction Adenocarcinoma

12/01/2022

Allison Casey

A propensity-matched comparison found that survival outcomes were equivalent for both FLOT chemotherapy regimen and the CROSS trimodality regimen among patients with gastroesophageal junction cancer.

A propensity-matched comparison...

12/01/2022

Oncology

News

Modified FLOT Improves Surgical Outcomes for Patients With Gastroesophageal Junction Adenocarcinoma

11/29/2022

Allison Casey

Among patients with gastroesophageal junction adenocarcinomas planned for curative resection, perioperative chemotherapy with the modified FLOT regimen was associated with improved resection rates and survival compared to the EOX regimen.

Among patients with...

11/29/2022

Oncology

News

Bemarituzumab Demonstrates Promising Clinical Efficacy in FGFR2b-Selected Gastric or GEJ Adenocarcinoma

11/03/2022

In a phase 2 trial, bemarituzumab demonstrated promising clinical efficacy, despite not reaching the primary end point of PFS, for patients with FGFR2b-selected gastric or gastroesophageal junction (GEJ) adenocarcinomas.

In a phase 2 trial,...

11/03/2022

Oncology

News

No Survival Benefit From Pertuzumab Plus Trastuzumab and Chemotherapy as First-Line Therapy for HER2-Positive Gastric/Gastroesophageal Junction Cancer

10/07/2022

Allison Casey

According to the final results from a phase 3 trial, there was no survival benefit from adding pertuzumab to trastuzumab and chemotherapy as a first-line therapy for patients with HER2-positive gastric or gastroesophageal junction cancer.

According to the final results...

10/07/2022

Oncology

News

The Potential for Neoadjuvant Nivolumab and Ipilimumab for Patients With Gastric or Gastroesophageal Junction Cancer

10/06/2022

In a phase 2 study, neoadjuvant nivolumab and ipilimumab followed by surgery and adjuvant nivolumab was found to be a feasible treatment option with a high pathological complete response rate in patients with gastric or gastroesophageal...

In a phase 2 study, neoadjuvant...

10/06/2022

Oncology

News

PD-L1 Expression Strong Predictor of Overall Survival Benefit From Immune Checkpoint Inhibition in Gastroesophageal Cancer

10/06/2022

Allison Casey

A systemic review and meta-analysis found that tissue-based PD-L1 expression is the strongest predictor of overall survival benefit from immune checkpoint inhibition for patients with advanced gastroesophageal cancer.

A systemic review and...

10/06/2022

Oncology

News

Anlotinib Plus Toripalimab Shows Promising Efficacy, Safety as Second-Line Treatment for Gastric and GEJ Carcinoma

08/04/2022

Allison Casey

Results of a phase 2 trial found that combined treatment with anlotinib and toripalimab showed promising efficacy and safety for gastric and gastroesophageal junction (GEJ) carcinoma in the second-line setting.

Results of a phase 2 trial found...

08/04/2022

Oncology

News

Certain Biomarkers Associated With Clinical Benefit From Tislelizumab in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

07/13/2022

Allison Casey

According to the results of 2 phase 1/2 trials, in advanced gastric/gastroesophageal junction adenocarcinoma PD-L1 positivity, IFNγ-related gene signatures, and TMB-high status were associated with gaining clinical benefit when treated with...

According to the results of 2...

07/13/2022

Oncology

News

Nivolumab Added to Trastuzumab and FOLFOX Improved Survival and Response Among Patients with ERBB2-Positive Gastroesophageal Adenocarcinoma

07/13/2022

Allison Casey

According to results from a phase 2 trial, the addition of nivolumab to trastuzumab and chemotherapy in the first-line setting for patients with ERBB2-positive gastric and gastroesophageal junction adenocarcinoma improved progression-free and...

According to results from a...

07/13/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology